{
  "docId": "019de072-7463-7169-8f31-7c4d89e9eac4",
  "docSlug": "d88eea3c6872c4e67cae911eb0680043",
  "documentTitle": "argenx SE | Results Presentation Deck | 10 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 2,
  "pageCount": 10,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "appendix_disclosure",
  "function": "other",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7463-7169-8f31-7c4d89e9eac4/2",
  "deckHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4",
  "deckJsonHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4.json",
  "deckAnchorHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.117,
        "w": 0.925,
        "x": 0.038,
        "y": 0.261
      },
      "kind": "list",
      "text": "The phase 3 ADAPT and ADAPT+ studies were funded by argenx\nJFH has received research support, honoraria, and nonfinancial support from argenx",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bbcad45-ea89-4b34-88a7-e1f02de0814c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.247,
        "w": 0.925,
        "x": 0.038,
        "y": 0.508
      },
      "kind": "paragraph",
      "text": "JFH has also received research support from Alexion Pharmaceuticals, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB), and Takeda Pharmaceuticals; Honoraria from Alexion Pharmaceuticals, Immunovant Inc, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi US and Viela Bio Inc. (now Horizon Therapeutics) and nonfinancial support from Alexion Pharmaceuticals, Ra Pharmaceuticals (now UCB) and Toleranzia AB",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9835dc08-07e0-4b68-a9c6-c970385ecfe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.167,
        "x": 0.038,
        "y": 0.064
      },
      "kind": "title",
      "text": "Disclosures",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04c4be71-3e4c-46cc-95f5-dfe8003fd25d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "438cbf55-8155-4d46-a46c-b3e3342ff915",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problem by showing the need for better therapies and the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}